Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 19Glioma 5Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Ovarian Neoplasms 3Neuroblastoma 3Medulloblastoma 3Glioblastoma 3Colorectal Neoplasms 3Rhabdoid Tumor 2Lymphoma 2Lung Neoplasms 2Liposarcoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oligodendroglioma 1

Interventions

Melphalan 4Irinotecan 4Filgrastim 4Cyclophosphamide 4Busulfan 4fludarabine 3Topotecan 3Temozolomide 3Granulocyte Colony-Stimulating Factor 3pegfilgrastim 2liposomal doxorubicin 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1ribociclib 1regorafenib 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1mocetinostat 1lexatumumab 1irinotecan sucrosofate 1fludarabine phosphate 1cixutumumab 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rhabdomyosarcoma × ribociclib × Clear all
NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Novartis

Phase 1 Terminated
12 enrolled
CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡